Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-221 vs Conventional Care Regimen in Relapsed/Refractory IDH2-mutant AML in Elderly Patients
CTR20170961Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enasidenib in acute myeloid leukemia (AML), sponsored by Celgene Corporation. Started Aug 2017; status: completed.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20170961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170961.